| ¿µ¹® | beta human chorionic gonadotropin | ÇÑ±Û | º£Å¸ »ç¶÷À¶¸ð¼º »ý½Ä»ùÀÚ±ØÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | Źݼ¼Æ÷¿¡¼ ¸¸µé¾îÁö´Â È£¸£¸ó. ±â´ÉÀº ÀÓ½ÅÀÇ Ãʱ⿡ Ȳü(¿ø·¡ ³ÀÚ¸¦ ½Î°í ÀÖ´ø ¼¼Æ÷µéÀÌ ¹è¶õÀÌ ÀϾ¼ ³ÀÚ°¡ ºüÁ®³ª°£ ÈÄ ÁÖ¸Ó´Ï ¸ð¾çÀ» ÀÌ·é °Í. ÀÓ½ÅÃʱ⿡ ÀÓ½ÅÀÇ À¯Áö¿¡ ÇÊ¿äÇÑ È£¸£¸óÀ» »ý¼ºÇÑ´Ù)ÀÇ À¯Áö¿¡ ±â¿©Çϰí, žÆÀÇ °íȯÁ¶Á÷¿¡¼ ³²¼ºÈ£¸£¸óÀÌ ºÐºñµÇ´Â °ÍÀ» ÃËÁø½ÃŲ´Ù. ¶Ç À̰ÍÀº ÀÓ½ÅÃʱâÀÇ ÀÓ»êºÎÀÇ ¼Òº¯¿¡¼ ¸¹Àº ¾çÀÌ °ËÃâµÇ¹Ç·Î À̰ÍÀ» ÀÌ¿ëÇØ¼ ÀÓ½ÅÀÇ ¿©ºÎ¸¦ ¼Õ½±°Ô Á¶»çÇÒ ¼ö°¡ ÀÖ´Ù. |
||
| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | acquired immunodeficiency syndrome | ÇÑ±Û | ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî |
|---|---|---|---|
| ¼³¸í | Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)¿¡ ÀÇÇÏ¿© ¸é¿ª ¼¼Æ÷°¡ ÆÄ±«µÊÀ¸·Î½á ÀÎüÀÇ ¸é¿ª´É·ÂÀÌ ±Øµµ·Î ÀúÇÏµÇ¾î º´¿øÃ¼¿¡ ´ëÇÏ¿© ¹«¹æºñ »óÅ¿¡ À̸£´Â º´. ¿¡ÀÌÁî ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â¸ç, 1981³â ¹Ì±¹¿¡¼ óÀ½ º¸°íµÇ¾ú´Ù. ÃÖÃÊ °¨¿°À¸·ÎºÎÅÍ Áõ»óÀÌ ³ªÅ¸³ª±â±îÁö´Â Æò±Õ 10³â Á¤µµ °É¸®¸ç »ç¸Á·üÀÌ ´ë´ÜÈ÷ ³ô´Ù. ¼ºÀû Á¢ÃË, ¿À¿° ÁÖ»ç±â »ç¿ë, ¿À¿° Ç÷¾× ¹× Ç÷¾× Á¦Á¦ »ç¿ë, ¿¡ÀÌÁî »ê¸ð·ÎºÎÅÍ ¼öÁ÷°¨¿° µûÀ§¿¡ ÀÇÇÏ¿© °¨¿°µÈ´Ù. °¨¿° ÈÄ Àϰú¼ºÀ¸·Î °¨±â¿Í °°Àº Áõ»óÀ» º¸ÀÌ¸ç ¹ÙÀÌ·¯½ºÇ÷ÁõÀ¸·Î µÇÁö¸¸ ¹ÙÀÌ·¯½º´Â °¨¼ÒµÇ°í 6~8ÁÖ ÈÄ¿¡´Â Ç×ü°¡ ¾ç¼ºÀ¸·Î µÈ´Ù. 6~10³â Á¤µµÀÇ ¹«ÁõÈļº º¸±Õ±â°£À» Áö³ª¼ ¿¡ÀÌÁî°ü·ÃÁõÈıº(AIDS related syndrome)À¸·Î µÈ´Ù. ÀúÇ×·ÂÀÇ °¨¼Ò, ¸²ÇÁÀýºñ´ë, üÁß°¨¼Ò, ¹ß¿, ¸¸¼º¼³»ç°¡ À̾îÁø´Ù. ±× ÈÄ ¿¡ÀÌÁî·Î µÇ¸ç, ÆóÆ÷ÀÚÃæÆó·Å µîÀÇ ¿øÃ溴, ĵð´Ù µîÀÇ Áø±ÕÁõ, Ç츣Æä½º¹ÙÀÌ·¯½º±º µîÀÇ ±âȸ°¨¿°ÀÌ À̾îÁø´Ù. ¶ÇÇÑ Ä«Æ÷½ÃÀ°Á¾, ¸²ÇÁÁ¾ µîÀ» º´¹ßÇØ¼ »ç¸ÁÇÑ´Ù. ¹ÙÀÌ·¯½ºÀÇ ³úÁ¶Á÷³» Áõ½ÄÀ¸·Î Ä¡¸Å¸¦ ÀÏÀ¸Å³ ¼öµµ ÀÖ´Ù. HIV-1Àº 10³â°£¿¡ »ç¸Á·üÀÌ 90%, HIV-2´Â 10%ÀÌ´Ù. |
||
| ¿µ¹® | virus | ÇÑ±Û | ¹ÙÀÌ·¯½º |
|---|---|---|---|
| ¼³¸í | ¹ÚÅ׸®¾Æº¸´Ù ´ú ÁøÈµÈ, »ý¹°°ú ¹«»ý¹°ÀÇ Áß°£´Ü°è¿¡ ÇØ´çÇÏ´Â °Í. È¥ÀÚ¼´Â »ýÁ¸´É·ÂÀÌ ¾øÀ¸¹Ç·Î ¹Ýµå½Ã ´Ù¸¥ ¼¼Æ÷³»¿¡ ¼ÓÇØ ÀÖ¾î¾ß ÇÑ´Ù. ÀÎü¿¡ ¹ß»ýÇÏ´Â ¸¹Àº º´Áß, ÀÌ ¹ÙÀÌ·¯½º·Î ÀÎÇØ ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ ¶§ ´ëºÎºÐ ƯÀÌÇÑ Ä¡·á¹ýÀº ¾ø´Â ½ÇÁ¤ÀÌ´Ù. ÀϺΠÇ츣Æä½º¹ÙÀÌ·¯½º °èÅë¿¡´Â Ä¡·á¾àÀÌ °³¹ßµÇ¾î ÀÖÁö¸¸, À̰͵µ ÀϺΠÁúº´¿¡¼¸¸ Ä¡·á°¡ °¡´ÉÇÏ´Ù. ¶ÇÇÑ, Ebstein-Barr virus, Human papilloma virus µîÀº ¾ÏÀÇ ¹ß»ý°ú ¿¬°üµÇ¾î ÀÖÀ¸¸ç, µ¿¹°¿¡¼ ¹ß»ýÇÏ´Â ´ëºÎºÐÀÇ ¾ÏÁ¾Àº ¹ÙÀÌ·¯½º¿Í ¿¬°üµÇ¾î ÀÖ´Â °æ¿ì°¡ ¸¹´Ù. ¿äÁò, ÀϺΠÁö¿ª¿¡¼ Å« À¯ÇàÀ» Çϰí ÀÖ´Â ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(AIDS)µµ HIV(Human Immunodeficiency Virus)¿Í °ü·ÃÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | simian virus | ÇÑ±Û | ¿ø¼þÀ̹ÙÀÌ·¯½º |
|---|---|---|---|
| ¼³¸í | ¿ø¼þÀÌ¿¡¼ ºÐ¸®µÈ ¹ÙÀÌ·¯½º. ¾Æµ¥³ë¹ÙÀÌ·¯½º, ¿£Å׷ιÙÀÌ·¯½º, Ç츣Æä½º¹ÙÀÌ·¯½º ¹× ·¹¿À¹ÙÀÌ·¯½º µîÀÇ ¿©·¯ ±º¿¡ ¼ÓÇÑ´Ù. |
||
| HEV | health and environment; hemagglutinating encephalomyelitis virus; hepatitis E virus; hepato-encephal... |
|---|---|
| CID | cellular immunodeficiency; charge injection device; chick infective dose; combined immunodeficiency ... |
| HIV | Human Immunodeficiency Virus |
| HIV | human immunodeficiency virus |
| HIV1 | human immunodeficiency virus type 1 |
| HIV/AIDS | Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
|---|---|
| HIV-2 | Human Immunodeficiency Virus type 1 and type 2 |
| HIV | Anti-human immunodeficiency virus |
| anti-HIV | Anti-human immunodeficiency virus |
| Anti-HIV-1 | Anti-human immunodeficiency virus type 1 |
| human immunodeficiency virus | <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified. Type 1: the retrovirus recognised as the agent that induces AIDS. Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa. Acronym: HIV (11 Nov 1997) |
|---|---|
| malignancy and immunodeficiency | <radiology> High risk of malignancy (especially lymphoma/leukaemia, GI tumours): X-linked agammaglobulinaemia (Bruton's), common variable immunodeficiency, severe combined immunodeficiency (SCID kids), ataxia-telangectasia, Wiscott-Aldrich syndrome, selective IgA deficiency (12 Dec 1998) |
| bovine immunodeficiency virus | A lentivirus causing lymphocytosis in cattle. (05 Mar 2000) |
| simian immunodeficiency virus | <virology> A retrovirus found in monkeys that is closely related to HIV. (09 Oct 1997) |
| immunodeficiency virus, bovine | A species of lentivirus, subgenus bovine lentiviruses (lentiviruses, bovine), found in cattle and causing lymphadenopathy, lymphocytosis, central nervous system lesions, progressive weakness, and emaciation. It has immunological cross-reactivity with other lentiviruses including HIV. (12 Dec 1998) |
| immunodeficiency virus, feline | A species of lentivirus, subgenus feline lentiviruses (lentiviruses, feline) isolated from cats with a chronic wasting syndrome, presumed to be immune deficiency. There is no antigenic relationship between fiv and HIV, nor does fiv grow in human T-cells. (12 Dec 1998) |
| feline immunodeficiency virus | A lentivirus causing acquired immunodeficiency in cats. (05 Mar 2000) |
| health and human services | See HHS. (12 Dec 1998) |
| united states dept. Of health and human services | A department of the united states government concerned with administering those agencies and offices having programs pertaining to health and human services. (12 Dec 1998) |
| maternal exposure | Exposure of the female parent, human or animal, to potentially harmful chemical, physical, or biological agents in the environment or to environmental factors that may include ionizing radiation, pathogenic organisms, or toxic chemicals that may affect offspring. It includes pre-conception maternal exposure. (12 Dec 1998) |
| maximum permissible exposure level | The highest level of exposure to a substance, usually noxious, in the environment or during diagnostic and therapeutic procedures, that a body can tolerate without injury. (12 Dec 1998) |
| paternal exposure | Exposure of the male parent, human or animal, to potentially harmful chemical, physical, or biological agents in the environment or to environmental factors that may include ionizing radiation, pathogenic organisms, or toxic chemicals that may affect offspring. (12 Dec 1998) |
| permissible exposure limit | An occupational health standard to safeguard workers against dangerous contaminants in the workplace. (05 Mar 2000) |
| prenatal exposure delayed effects | Delayed effects on offspring of maternal or foetal prenatal exposure to drugs, radiation and other physical agents, manipulation, nutrition, stress, etc. (12 Dec 1998) |
| short-term exposure limit | The maximum concentration of a chemical to which workers may be exposed continuously for up to 15 minutes without danger to health or work efficiency and safety. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|